These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 34280914)

  • 21. CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape.
    Sun S; Zou H; Li L; Liu Q; Ding N; Zeng L; Li H; Mao S
    Int J Pharm; 2019 Sep; 568():118518. PubMed ID: 31319147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD33 directed bispecific antibodies in acute myeloid leukemia.
    Clark MC; Stein A
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101224. PubMed ID: 33279180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD33-Targeted Therapies: Beating the Disease or Beaten to Death?
    Maakaron JE; Rogosheske J; Long M; Bachanova V; Mims AS
    J Clin Pharmacol; 2021 Jan; 61(1):7-17. PubMed ID: 32875599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What happened to anti-CD33 therapy for acute myeloid leukemia?
    Jurcic JG
    Curr Hematol Malig Rep; 2012 Mar; 7(1):65-73. PubMed ID: 22109628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
    Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
    Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.
    Cowan AJ; Laszlo GS; Estey EH; Walter RB
    Front Biosci (Landmark Ed); 2013 Jun; 18(4):1311-34. PubMed ID: 23747885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemtuzumab ozogamicin in acute myeloid leukemia.
    Godwin CD; Gale RP; Walter RB
    Leukemia; 2017 Sep; 31(9):1855-1868. PubMed ID: 28607471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
    Linenberger ML
    Leukemia; 2005 Feb; 19(2):176-82. PubMed ID: 15592433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody-Based Treatment of Acute Myeloid Leukemia.
    Garfin PM; Feldman EJ
    Curr Hematol Malig Rep; 2016 Dec; 11(6):545-552. PubMed ID: 27734262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MoS
    Wang J; Sui L; Huang J; Miao L; Nie Y; Wang K; Yang Z; Huang Q; Gong X; Nan Y; Ai K
    Bioact Mater; 2021 Nov; 6(11):4209-4242. PubMed ID: 33997503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting acute myeloid leukemia cells by CD33 receptor-specific MoS
    Štefík P; Annušová A; Lakatoš B; Elefantová K; Čepcová L; Hofbauerová M; Kálosi A; Jergel M; Majková E; Šiffalovič P
    Biomed Mater; 2021 Aug; 16(5):. PubMed ID: 34280914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The past and future of CD33 as therapeutic target in acute myeloid leukemia.
    Laszlo GS; Estey EH; Walter RB
    Blood Rev; 2014 Jul; 28(4):143-53. PubMed ID: 24809231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An insight into the dual role of MoS2-based nanocarriers in anticancer drug delivery and therapy.
    Ghosh S; Lai JY
    Acta Biomater; 2024 Apr; 179():36-60. PubMed ID: 38552760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia.
    Laing AA; Harrison CJ; Gibson BES; Keeshan K
    Exp Hematol; 2017 Oct; 54():40-50. PubMed ID: 28668350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigational CD33-targeted therapeutics for acute myeloid leukemia.
    Walter RB
    Expert Opin Investig Drugs; 2018 Apr; 27(4):339-348. PubMed ID: 29534618
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.